Quality Assurance Program for Clinical Measurement of Antiretrovirals: AIDS Clinical Trials Group Proficiency Testing Program for Pediatric and Adult Pharmacology Laboratories

Diane T. Holland, Robin DiFrancesco, Judith Stone, Fayez Hamzeh, James D. Connor, Gene D. Morse

Research output: Contribution to journalArticle

Abstract

Clinical trials designed to compare antiretroviral regimens, investigate therapeutic drug monitoring, or measure pharmacometrics often include protease inhibitors (PIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs), and nucleoside reverse transcriptase inhibitors, requiring the measurement of these antiretrovirals in plasma. Within the adult and pediatric AIDS Clinical Trials Group (ACTG), a network of Pharmacology Support Laboratories (PSLs) is a component of the group laboratory infrastructure and conducts these types of pharmacologic assays. The adult ACTG has developed a comprehensive quality assurance program for the conduct of clinical pharmacology protocols, one component of which is the antiretroviral proficiency testing (PT) program that has been implemented between the adult and pediatric pharmacology laboratories of the ACTG. PT testing samples were prepared and distributed in July 2001, February 2002, and July 2002. High, medium, and low concentrations of PIs (indinavir, saquinavir, amprenavir, lopinavir, ritonavir, and nelfinavir) and NNRTIs (nevirapine and efavirenz) were added to drug-free EDTA plasma and distributed, on dry ice, to eight ACTG PSLs. One testing laboratory used liquid chromatography-tandem mass spectrometry, and seven used high-performance liquid chromatography-UV analysis. A result was considered acceptable if it was within 20% deviation of the assigned concentration. For all concentrations of PIs evaluated, 96% of samples tested (430 of 448 measurements) met the acceptance criteria. For both NNRTIs, 100% of samples tested (140 of 140 measurements) met the acceptance criteria. In conclusion, the PT program results presented demonstrate excellent interlaboratory agreement for all antiretrovirals tested and provide support for the merger of plasma concentration data among laboratories for large clinical trials.

Original languageEnglish (US)
Pages (from-to)824-831
Number of pages8
JournalAntimicrobial Agents and Chemotherapy
Volume48
Issue number3
DOIs
StatePublished - Mar 2004
Externally publishedYes

Fingerprint

Acquired Immunodeficiency Syndrome
Reverse Transcriptase Inhibitors
Clinical Trials
Pharmacology
Pediatrics
Protease Inhibitors
efavirenz
Dry Ice
Nelfinavir
Saquinavir
Lopinavir
Indinavir
Nevirapine
Ritonavir
Clinical Pharmacology
Drug Monitoring
Clinical Protocols
Tandem Mass Spectrometry
Nucleosides
Edetic Acid

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Quality Assurance Program for Clinical Measurement of Antiretrovirals : AIDS Clinical Trials Group Proficiency Testing Program for Pediatric and Adult Pharmacology Laboratories. / Holland, Diane T.; DiFrancesco, Robin; Stone, Judith; Hamzeh, Fayez; Connor, James D.; Morse, Gene D.

In: Antimicrobial Agents and Chemotherapy, Vol. 48, No. 3, 03.2004, p. 824-831.

Research output: Contribution to journalArticle

Holland, Diane T. ; DiFrancesco, Robin ; Stone, Judith ; Hamzeh, Fayez ; Connor, James D. ; Morse, Gene D. / Quality Assurance Program for Clinical Measurement of Antiretrovirals : AIDS Clinical Trials Group Proficiency Testing Program for Pediatric and Adult Pharmacology Laboratories. In: Antimicrobial Agents and Chemotherapy. 2004 ; Vol. 48, No. 3. pp. 824-831.
@article{6799bd0a647a4c5dbca7dab6a7c86a0d,
title = "Quality Assurance Program for Clinical Measurement of Antiretrovirals: AIDS Clinical Trials Group Proficiency Testing Program for Pediatric and Adult Pharmacology Laboratories",
abstract = "Clinical trials designed to compare antiretroviral regimens, investigate therapeutic drug monitoring, or measure pharmacometrics often include protease inhibitors (PIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs), and nucleoside reverse transcriptase inhibitors, requiring the measurement of these antiretrovirals in plasma. Within the adult and pediatric AIDS Clinical Trials Group (ACTG), a network of Pharmacology Support Laboratories (PSLs) is a component of the group laboratory infrastructure and conducts these types of pharmacologic assays. The adult ACTG has developed a comprehensive quality assurance program for the conduct of clinical pharmacology protocols, one component of which is the antiretroviral proficiency testing (PT) program that has been implemented between the adult and pediatric pharmacology laboratories of the ACTG. PT testing samples were prepared and distributed in July 2001, February 2002, and July 2002. High, medium, and low concentrations of PIs (indinavir, saquinavir, amprenavir, lopinavir, ritonavir, and nelfinavir) and NNRTIs (nevirapine and efavirenz) were added to drug-free EDTA plasma and distributed, on dry ice, to eight ACTG PSLs. One testing laboratory used liquid chromatography-tandem mass spectrometry, and seven used high-performance liquid chromatography-UV analysis. A result was considered acceptable if it was within 20{\%} deviation of the assigned concentration. For all concentrations of PIs evaluated, 96{\%} of samples tested (430 of 448 measurements) met the acceptance criteria. For both NNRTIs, 100{\%} of samples tested (140 of 140 measurements) met the acceptance criteria. In conclusion, the PT program results presented demonstrate excellent interlaboratory agreement for all antiretrovirals tested and provide support for the merger of plasma concentration data among laboratories for large clinical trials.",
author = "Holland, {Diane T.} and Robin DiFrancesco and Judith Stone and Fayez Hamzeh and Connor, {James D.} and Morse, {Gene D.}",
year = "2004",
month = "3",
doi = "10.1128/AAC.48.3.824-831.2004",
language = "English (US)",
volume = "48",
pages = "824--831",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "3",

}

TY - JOUR

T1 - Quality Assurance Program for Clinical Measurement of Antiretrovirals

T2 - AIDS Clinical Trials Group Proficiency Testing Program for Pediatric and Adult Pharmacology Laboratories

AU - Holland, Diane T.

AU - DiFrancesco, Robin

AU - Stone, Judith

AU - Hamzeh, Fayez

AU - Connor, James D.

AU - Morse, Gene D.

PY - 2004/3

Y1 - 2004/3

N2 - Clinical trials designed to compare antiretroviral regimens, investigate therapeutic drug monitoring, or measure pharmacometrics often include protease inhibitors (PIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs), and nucleoside reverse transcriptase inhibitors, requiring the measurement of these antiretrovirals in plasma. Within the adult and pediatric AIDS Clinical Trials Group (ACTG), a network of Pharmacology Support Laboratories (PSLs) is a component of the group laboratory infrastructure and conducts these types of pharmacologic assays. The adult ACTG has developed a comprehensive quality assurance program for the conduct of clinical pharmacology protocols, one component of which is the antiretroviral proficiency testing (PT) program that has been implemented between the adult and pediatric pharmacology laboratories of the ACTG. PT testing samples were prepared and distributed in July 2001, February 2002, and July 2002. High, medium, and low concentrations of PIs (indinavir, saquinavir, amprenavir, lopinavir, ritonavir, and nelfinavir) and NNRTIs (nevirapine and efavirenz) were added to drug-free EDTA plasma and distributed, on dry ice, to eight ACTG PSLs. One testing laboratory used liquid chromatography-tandem mass spectrometry, and seven used high-performance liquid chromatography-UV analysis. A result was considered acceptable if it was within 20% deviation of the assigned concentration. For all concentrations of PIs evaluated, 96% of samples tested (430 of 448 measurements) met the acceptance criteria. For both NNRTIs, 100% of samples tested (140 of 140 measurements) met the acceptance criteria. In conclusion, the PT program results presented demonstrate excellent interlaboratory agreement for all antiretrovirals tested and provide support for the merger of plasma concentration data among laboratories for large clinical trials.

AB - Clinical trials designed to compare antiretroviral regimens, investigate therapeutic drug monitoring, or measure pharmacometrics often include protease inhibitors (PIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs), and nucleoside reverse transcriptase inhibitors, requiring the measurement of these antiretrovirals in plasma. Within the adult and pediatric AIDS Clinical Trials Group (ACTG), a network of Pharmacology Support Laboratories (PSLs) is a component of the group laboratory infrastructure and conducts these types of pharmacologic assays. The adult ACTG has developed a comprehensive quality assurance program for the conduct of clinical pharmacology protocols, one component of which is the antiretroviral proficiency testing (PT) program that has been implemented between the adult and pediatric pharmacology laboratories of the ACTG. PT testing samples were prepared and distributed in July 2001, February 2002, and July 2002. High, medium, and low concentrations of PIs (indinavir, saquinavir, amprenavir, lopinavir, ritonavir, and nelfinavir) and NNRTIs (nevirapine and efavirenz) were added to drug-free EDTA plasma and distributed, on dry ice, to eight ACTG PSLs. One testing laboratory used liquid chromatography-tandem mass spectrometry, and seven used high-performance liquid chromatography-UV analysis. A result was considered acceptable if it was within 20% deviation of the assigned concentration. For all concentrations of PIs evaluated, 96% of samples tested (430 of 448 measurements) met the acceptance criteria. For both NNRTIs, 100% of samples tested (140 of 140 measurements) met the acceptance criteria. In conclusion, the PT program results presented demonstrate excellent interlaboratory agreement for all antiretrovirals tested and provide support for the merger of plasma concentration data among laboratories for large clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=1442275675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1442275675&partnerID=8YFLogxK

U2 - 10.1128/AAC.48.3.824-831.2004

DO - 10.1128/AAC.48.3.824-831.2004

M3 - Article

C2 - 14982771

AN - SCOPUS:1442275675

VL - 48

SP - 824

EP - 831

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 3

ER -